Treatment Study for Patients with Node-Positive Breast Cancer

Clinical Trial Title

A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.

National Clinical Trial Number:

NCT01901094

Clinical Trial Protocol Description:

This study is accepting patients at both Rush University Medical Center and Rush Copley Medical Center. Please see contact information below to join the study at one location.

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy X-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to start of neoadjuvant chemotherapy).
  • Have no inflammatory breast cancer.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator at Rush University Medical Center

Parul Barry, MD

Rush University Medical Center Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Investigator at Rush Copley Medical Center

Joseph T. Meschi, MD

Rush Copley Medical Center Contact Information

Amanda Baker